Cardiovascular Journal of Africa: Vol 32 No 6 (NOVEMBER/DECEMBER 2021)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 6, November/December 2021 336 AFRICA is associated with increased activity of protein phosphatases. Circulation 2004; 110 (17): 2651–2657. 36. Dinanian S, Boixel C, Juin C, Hulot JS, Coulombe A, Rücker-Martin C, et al . Down-regulation of the calcium current in human right atrial myocytes from patients in sinus rhythm but with a high risk of atrial fibrillation. Eur Heart J 2008; 29 : 1190–1197. 37. Kaori S, Akiko S-T, Gernot S, Stanley N. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium. Circulation 2003; 107 (10): 1440–1446. 38. Singh BN. Amiodarone: Historical development and pharmacologic profile. Am Heart J 1983; 106 (4 Part 2): 788–797. 39. Gottlieb SS, Riggio DW, Lauria S, Peters RW, Shorofsky SR, Cines M, et al . High dose oral amiodarone loading exerts important hemody- namic actions in patients with congestive heart failure. J Am Coll Cardiol 1994; 23 (3): 560–564. 40. Andreasen F, Agerbæk H, Bjerregaard P, Gøtzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981; 19 (4): 293–299. 41. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: Experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J 1984; 108 (4 Part 1): 890–898. 42. Waleffe A, Bruninx P, Kulbertus HE. Effects of amiodarone studied by programmed electrical stimulation of the heart in patients with parox- ysmal re-entrant supraventricular tachycardia. J Electrocardiol 1978; 11 (3): 253–260. 43. Touboul P, Atallah G, Gressard A, Kirkorian G. Effects of amiodarone on sinus node in man. Br Heart J 1979; 42 (5): 573–578. 44. Rasmussen V, Berning J. Effect of amiodarone in the Wolff–Parkinson– White syndrome: a clinical and electrophysiological study. Acta Med Scand 1979; 205 (1–6): 31–37. 45. Wellens HJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984; 69 (1): 120–124. 46. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012; 125 (2): 381–389. 47. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2019; 9 (9): CD005049. 48. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011; 13 (3): 329– 345. 49. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrilla- tion. Am J Cardiol 2012; 110 (5): 673– 677. 50. Santas E, Dominguez E, Martinez-Brotons A, Ruiz-Granell R, Ruiz V, Ferrero A, et al . Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective rand- omized study. Eur Heart J 2012; 33 (Suppl 1): 380. 51. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evalu- ate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The dionysos study. J Cardiovasc Electrophysiol 2010; 21 (6): 597–605. 52. Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, et al . A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: AGroup for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J 2008; 155 (1): 100–107. 53. Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, et al . A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J 2006; 151 (4): 863. 54. Niu F, Huang C, Jiang H, Yang B, Guo W, Chen YX, et al . Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi 2006; 86 (2): 121–123. 55. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al . Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352 (18): 1861–1872. 56. Kochiadakis GE, Igoumenidis NE, Hamilos MI, Tzerakis PG, Klapsinos NC, Zacharis EA, et al . Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest 2004; 125 (2): 377–383. 57. Kanoupakis EM, Manios EG, Mavrakis HE, Tzerakis PG, Mouloudi HK, Vardas PE. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol 2004; 94 (5): 659–662. 58. Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, et al . Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a rand- omized controlled study. Cardiovasc Drugs Ther 2003; 17 (1): 31–39. 59. Greene HL. Maintenance of sinus rhythm in patients with atrial fibrilla- tion: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42 (1): 20–29. 60. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000; 84 (3): 251–257. 61. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al . Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342 (13): 913– 920. 62. Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C. Comparison of intra- venous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86 (9): 950–953. 63. Villani R, Zoletti F, Veniani M, Locati F, Nava S. A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation. Clin Ter 1992; 140 (1 Pt 2): 35–39. 64. Zehender M, Hohnloser S, Müller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19 (5): 1054–1059. 65. Martin A, Benbow LJ, Leach C, Bailey RJ. Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report). Br J Clin Pract 1986; 44 (Suppl): 52–60. 66. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981; 36 (6): 431–444. 67. Perrone MA, Babu Dasari J, Intorcia A, Morgagni R, Sergi D, Battaini F, et al . Efficacy and safety of dronedarone in patients with amiodarone- induced hyperthyroidism: A clinical study. Eur Rev Med Pharmacol Sci 2018; 22 (23): 8502–8508. 68. Tsanaxidis N, Aidonidis I, Hatziefthimiou A, Daskalopoulou SS, Giamouzis G, Triposckiadis F, et al. Ranolazine added to amiodarone